Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Anaptysbio, inc. crawled time : 14:01 save search
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
Published: 2020-08-10 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: -3.2%
H: 3.53%
C: -1.12%
financial results results
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
Published: 2020-09-11 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
| Email alert
Add to watchlist
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
Published: 2020-10-13 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: 1.01%
H: 5.5%
C: 4.96%
phase 2 positive trial topline psoriasis
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
Published: 2020-10-26 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: 1.36%
H: 9.93%
C: 6.33%
collaboration
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
Published: 2020-11-04 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: -0.47%
H: 3.83%
C: -0.85%
financial results results
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
Published: 2020-11-13 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: 1.02%
H: 0.77%
C: -1.61%
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium -- Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
Published: 2021-01-16 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
| Email alert
Add to watchlist
test positive cancer gastrointestinal symposium dostarlimab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.